• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Adjunctive dexamethasone in HIV-cryptococcal meningitis linked with increased morbidity and mortality: The CryptoDex study

byMatthew Lin, MDandShaidah Deghan, MSc. MD
February 15, 2016
in Infectious Disease, Neurology, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Adjunctive dexamethasone for HIV-associated cryptococcal meningitis did not reduce mortality.

2. Adjunctive dexamethasone for HIV-associated cryptococcal meningitis was associated with more adverse events and disability compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: HIV-associated cryptococcal meningitis causes approximately 600,000 deaths each year. For certain CNS infections, such as bacterial meningitis, glucocorticoids as adjunctive therapy has shown some benefits. Such benefit is believed to be derived from a reduction in ICP and inflammation. In general, there is little data on the effects of glucocorticoids in HIV-associated cryptococcal meningitis. In this randomized, double-blind, placebo-controlled study, researchers found that adjunctive dexamethasone therapy in HIV-cryptococcal meningitis was associated with significantly increased mortality and disability, more adverse events and a slower decline in CSF counts of infection compared with the placebo group.

Click to read the study in NEJM

Relevant Reading: Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis

In-Depth [randomized controlled trial]: In this double-blind, randomized placebo-controlled trial, researchers evaluated the effect of adjunctive dexamethasone on the morbidity and mortality of patients with HIV-associated cryptococcal meningitis. A total of 451 patients from 13 hospitals in Indonesia, Laos, Thailand, Vietnam, Malawi and Uganda were enrolled with 224 and 227 patients assigned to the dexamethasone and placebo groups respectively. The primary outcome was survival at 10 weeks after randomization. Notable secondary outcomes included disability (ranked as good, intermediate, poor or death) at 10 weeks and 6 months, visual acuity at 10 weeks, cryptococcal CSF counts and change in opening pressure during the first two weeks.

RELATED REPORTS

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

Several factors influence health programs conducted in the African American Church

Liposomal amphotericin B noninferior to standard treatment for cryptococcal meningitis

At 10 weeks, 47% in the dexamethasone group vs. 41% in the placebo group had died. While the initial intention-to-treat analysis showed no significant differences in the primary outcome (HR for death in dexamethasone group=1.11; 95%[CI] = 0.84-1.47; p=0.45), an exploratory analysis stratifying deaths by months showed significant differences in death between days 44-71 (HR=2.50, 95%[CI]=1.23-5.05; p=0.01). Disability at 10 weeks and 6 months was significantly associated with dexamethasone (10 weeks OR of 0.43; 95%[CI]=0.25-0.69; p<0.001; and 6 months OR=0.49; 95%[CI]=0.31-0.77; p=0.002). The rate of decline in CSF counts of infection per day was −0.21 log10  colony-forming units per milliliter in the dexamethasone group vs −0.31 log10  colony-forming units per milliliter in the placebo group (P<0.001). Additionally, at 6 months, there were 667 clinical adverse events in the dexamethasone group and 494 in the placebo group (p=0.01). After approximately 18 months, the clinical trial was stopped over concern that dexamethasone was causing harm in multiple outcomes categories.

Image: PD/CDC

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bacterial meningitiscryptococcusHIV
Previous Post

Differential RNA expression in late onset fetal growth restriction

Next Post

Erythropoiesis-stimulating agents linked to improved cognition in preterm infants

RelatedReports

Gardasil vaccine demonstrates immunogenic response at 10-year follow-up
Chronic Disease

Long-acting cabotegravir significantly decreases incidence of HIV compared to daily oral tenofovir

May 18, 2022
Wellness

Several factors influence health programs conducted in the African American Church

May 18, 2022
Pre-exposure prophylaxis (PrEP) effective in preventing HIV infection in high-risk gay men
Chronic Disease

Liposomal amphotericin B noninferior to standard treatment for cryptococcal meningitis

March 29, 2022
Increased frailty associated with childhood cancer survivorship
Oncology

Pembrolizumab as a promising treatment in patients with classic or endemic Kaposi’s sarcoma

March 27, 2022
Next Post
Digital imaging detects sight-threatening retinopathy of prematurity

Erythropoiesis-stimulating agents linked to improved cognition in preterm infants

Hormone levels independent of BMI with contraceptive implant

Obesity in critically ill children associated with increased mortality

Being overweight and obese associated with increased incidence of chronic kidney disease

Erythropoietin-stimulating agents may not improve quality of life for patients with chronic kidney disease

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.